Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity
NCT ID: NCT02148562
Last Updated: 2014-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
274 participants
OBSERVATIONAL
2014-04-30
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biologic Basis of Liver Cancer From Chronic Hepatitis B
NCT03300414
Mutations of the Pre-core Region of Hepatite B Virus (HBV)
NCT03625258
New HBV Infection Biomarkers: Clinical Characterization and Impact on Management
NCT06906016
The Development of Diagnostic Biomarker Panels for Hepatitis and Liver Cancer
NCT01310062
"Real-life" Cohort of Patients With Chronic Hepatitis B Virus Infection
NCT01732081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Hepatitis B
Diagnosis of Hepatitis B related liver disease in a pre-advanced stage
No interventions assigned to this group
End stage liver disease
Diagnosis of advanced liver disease related to Hepatitis B
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical diagnosis of advanced liver disease related to chronic Hepatitis B infection (cirrhosis, hepatocellular carcinoma,..)
* Availability of serum samples
Control group:
* Clinical diagnosis of liver disease related to chronic Hepatitis B infection in a pre-advanced stage
* Matched demographic and geographic characteristics to study group
* Availability of serum samples
Exclusion Criteria
* Patients with auto-immune diseases
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fund for Scientific Research, Flanders, Belgium
OTHER
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MahmoudReza Pourkarim
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
MahmoudReza Pourkarim, PhD
Role: PRINCIPAL_INVESTIGATOR
UZ Leuven campus Gasthuisberg, Herestraat 49. 3000 Leuven, Belgium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Leuven campus Gasthuisberg
Leuven, Flemish Brabant, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12G1714N
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
S56121
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.